Drug intelligence / Profile preview

macroaggregated albumin

Development stage
Approved
Lead developer
Jubilant DraxImage
Modality
Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
Administration
Intravenous, Intraperitoneal
01

Overview

Macroaggregated albumin is a biologic agent composed of human serum albumin that has been denatured and aggregated into particles by controlled heating. When labeled with the radioisotope technetium‑99m, it forms technetium Tc 99m macroaggregated albumin (Tc‑99m MAA), a radiopharmaceutical used primarily for diagnostic imaging. The primary clinical applications are in lung perfusion scintigraphy to assess pulmonary blood flow and in evaluating the patency of peritoneovenous (LeVeen) shunts. The mechanism involves intravenous injection of the radiolabeled aggregates, which become temporarily lodged in pulmonary capillaries due to their particle size; gamma emissions from technetium‑99m are then detected using gamma cameras to visualize regional blood flow. Macroaggregated albumin is metabolized by the reticuloendothelial system after clearance from capillary beds[2][3][4][5][7][8].

Brand names
PulmoliteTechnescan MAAMPI MAAPulmotech MAA
Other names
albumin aggregatedalbumin, aggregatedtechnetium tc 99m albumin aggregatedTc 99m macroaggregated albuminTc99m macroaggregated albuminTc-99m macroaggregated albuminTc 99m MAATc99m MAATc-99m MAA

Beyond the preview

Go deeper on macroaggregated albumin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on macroaggregated albumin.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call